Loading...
XTAI
1786
Market cap253mUSD
Jul 15, Last price  
103.00TWD
1D
0.98%
1Q
9.11%
Jan 2017
113.07%
IPO
112.20%
Name

SciVision Biotech Inc

Chart & Performance

D1W1MN
No data to show
P/E
30.69
P/S
8.42
EPS
3.36
Div Yield, %
4.67%
Shrs. gr., 5y
0.31%
Rev. gr., 5y
15.07%
Revenues
883m
+23.89%
15,682,00066,215,000143,271,000200,680,000200,509,000158,281,000264,842,000228,304,000258,418,000329,581,000437,873,000466,881,000505,539,000557,348,000712,988,000883,310,000
Net income
242m
+36.17%
-52,535,000-6,864,00051,161,00062,430,00040,352,000-22,145,00054,840,000-26,263,00017,139,00086,869,000120,703,000128,005,000101,720,000141,716,000177,900,000242,254,000
CFO
270m
-0.79%
-36,088,0006,847,00037,127,00051,517,00037,275,0001,852,00049,807,00038,286,00015,978,000111,699,000204,400,000126,470,00098,507,000178,207,000272,012,000269,873,000
Dividend
Jul 26, 20242.28227 TWD/sh

Profile

SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.
URL
https://www.scivision.com.tw/
IPO date
Dec 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
883,310
23.89%
712,988
27.93%
557,348
10.25%
Cost of revenue
635,200
513,350
422,737
Unusual Expense (Income)
NOPBT
248,110
199,638
134,611
NOPBT Margin
28.09%
28.00%
24.15%
Operating Taxes
49,344
32,097
31,834
Tax Rate
19.89%
16.08%
23.65%
NOPAT
198,766
167,541
102,777
Net income
242,254
36.17%
177,900
25.53%
141,716
39.32%
Dividends
(169,328)
(133,301)
(93,830)
Dividend yield
2.28%
2.25%
2.32%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
139,513
1,216
5,260
Long-term debt
174,174
370,767
436,089
Deferred revenue
Other long-term liabilities
31,286
41,949
48,379
Net debt
(392,385)
(432,073)
(147,678)
Cash flow
Cash from operating activities
269,873
272,012
178,207
CAPEX
(34,763)
(14,734)
(14,964)
Cash from investing activities
97,516
(213,365)
49,593
Cash from financing activities
(172,518)
(134,530)
(299,714)
FCF
109,572
238,896
190,335
Balance
Cash
871,426
804,056
673,887
Long term investments
(165,354)
(84,860)
Excess cash
661,906
768,407
561,160
Stockholders' equity
964,579
947,797
886,136
Invested Capital
1,490,666
1,247,960
1,400,227
ROIC
14.52%
12.65%
7.20%
ROCE
11.50%
9.90%
6.86%
EV
Common stock shares outstanding
71,468
76,442
74,658
Price
104.00
34.02%
77.60
43.17%
54.20
9.27%
Market cap
7,432,620
25.30%
5,931,899
46.59%
4,046,464
14.94%
EV
7,040,235
5,499,826
3,898,786
EBITDA
313,338
262,769
196,669
EV/EBITDA
22.47
20.93
19.82
Interest
5,673
8,220
6,458
Interest/NOPBT
2.29%
4.12%
4.80%